RCM
OVID icon

RA Capital Management’s Ovid Therapeutics OVID Stock Holding History

RA Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.8M Hold
10,714,000
– – 0.25% 53
2025
Q4 		$17.5M Buy
+10,714,000
New +$16.5M 0.18% 51
2021
Q1 		– Sell
-285,000
Closed -$658K – 92
2020
Q4 		$658K Hold
285,000
– – 0.01% 82
2020
Q3 		$1.64M Hold
285,000
– – 0.03% 70
2020
Q2 		$2.1M Buy
+285,000
New +$1.33M 0.04% 56

Other funds holding OVID

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

RA Capital Management's OVID Position: Q1 2026 in Review

RA Capital Management held its Ovid Therapeutics (OVID) position steady in Q1 2026 at 10,714,000 shares worth $23.8M. The position accounts for 0.25% of the portfolio, ranked #53.

RA Capital Management first reported a position in OVID in Q2 2020 and has held it in 5 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • RA Capital Management held 10,714,000 shares of Ovid Therapeutics worth $23.8M as of Q1 2026.
  • RA Capital Management left its Ovid Therapeutics share count unchanged in Q1 2026.
  • Ovid Therapeutics made up 0.25% of RA Capital Management's portfolio in Q1 2026, its #53 holding.
  • RA Capital Management first reported a position in Ovid Therapeutics in Q2 2020 and has held it in 5 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.